[go: up one dir, main page]

PL2057156T3 - Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR - Google Patents

Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR

Info

Publication number
PL2057156T3
PL2057156T3 PL07789277T PL07789277T PL2057156T3 PL 2057156 T3 PL2057156 T3 PL 2057156T3 PL 07789277 T PL07789277 T PL 07789277T PL 07789277 T PL07789277 T PL 07789277T PL 2057156 T3 PL2057156 T3 PL 2057156T3
Authority
PL
Poland
Prior art keywords
pyrazo
pyrimido
pyrido
methylmorpholine
pyrimidine derivatives
Prior art date
Application number
PL07789277T
Other languages
English (en)
Inventor
Heather Mary Ellen Duggan
Frederic Georges Marie Leroux
Karine Malagu
Niall Morrisson Barr Martin
Keith Allan Menear
Graeme Cameron Murray Smith
Original Assignee
Kudos Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38537521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2057156(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kudos Pharmaceuticals Limited filed Critical Kudos Pharmaceuticals Limited
Publication of PL2057156T3 publication Critical patent/PL2057156T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07789277T 2006-08-23 2007-08-21 Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR PL2057156T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82331106P 2006-08-23 2006-08-23
US93877607P 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
PL2057156T3 true PL2057156T3 (pl) 2017-08-31

Family

ID=38537521

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07789277T PL2057156T3 (pl) 2006-08-23 2007-08-21 Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR

Country Status (29)

Country Link
US (6) US7902189B2 (pl)
EP (1) EP2057156B1 (pl)
JP (2) JP5227321B2 (pl)
KR (1) KR101438245B1 (pl)
AR (1) AR062503A1 (pl)
AU (1) AU2007287430B2 (pl)
BR (1) BRPI0715888B1 (pl)
CA (1) CA2659851C (pl)
CL (1) CL2007002448A1 (pl)
CO (1) CO6150164A2 (pl)
CY (1) CY1119381T1 (pl)
DK (1) DK2057156T3 (pl)
ES (1) ES2648388T3 (pl)
HR (1) HRP20170627T1 (pl)
HU (1) HUE033894T2 (pl)
IL (1) IL196775A (pl)
LT (1) LT2057156T (pl)
MX (1) MX2009001946A (pl)
MY (1) MY148688A (pl)
NO (1) NO342383B1 (pl)
NZ (1) NZ575672A (pl)
PL (1) PL2057156T3 (pl)
PT (1) PT2057156T (pl)
RS (1) RS55881B1 (pl)
RU (1) RU2445312C2 (pl)
SA (1) SA07280461B1 (pl)
SI (1) SI2057156T1 (pl)
TW (1) TWI406863B (pl)
WO (1) WO2008023161A1 (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974129B1 (en) * 1996-09-04 2006-08-16 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
BRPI0715888B1 (pt) 2006-08-23 2021-11-03 Kudos Pharmaceuticals Limited Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP2011500657A (ja) * 2007-10-15 2011-01-06 アストラゼネカ アクチボラグ 組合せ０５９
CA2715181A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
ES2398423T3 (es) 2008-06-20 2013-03-19 Astrazeneca Ab Composiciones con y procedimiento para pirido[2,3-D]pirimidinas sustituídas con metilmorfolina
EP2318377B1 (en) * 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
PL2308877T3 (pl) 2008-08-05 2014-07-31 Daiichi Sankyo Co Ltd Pochodne imidazopirydyn-2-onu
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
ES2548141T3 (es) * 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
KR20110115160A (ko) 2009-02-12 2011-10-20 메르크 세로노 에스. 에이. 2-모르폴리노-피리도〔3,2-ｄ〕피리미딘
EP2427174A4 (en) * 2009-05-04 2014-01-15 Santen Pharmaceutical Co Ltd HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
BR112012011188A2 (pt) 2009-11-12 2021-06-29 F.Hoffmann - La Roche Ag ''composto,composição farmacêutica e uso de um composto"
US8828990B2 (en) 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
US20120232087A1 (en) 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
MX2012009030A (es) 2010-02-03 2012-09-12 Signal Pharm Llc Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa.
US8748428B2 (en) 2010-03-30 2014-06-10 Novartis Ag Use of a PKC inhibitor
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
MX2013006858A (es) 2010-12-16 2013-07-29 Hoffmann La Roche Compuesto triciclicos inhibidores de la pi3k y metodos de uso.
EP2726108B1 (en) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
MX2014001246A (es) 2011-08-03 2014-06-11 Signal Pharm Llc Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
RU2014149145A (ru) 2012-05-23 2016-07-20 Ф. Хоффманн-Ля Рош Аг Композиции и способы получения и применения эндодермальных клеток и гепатоцитов
US9914730B2 (en) * 2012-09-28 2018-03-13 Cancer Research Technology Limited Azaquinazoline inhibitors of Atypical protein Kinase C
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2948447B1 (en) 2013-01-23 2016-09-21 Astrazeneca AB Chemical compounds
EP2968317A4 (en) * 2013-03-15 2016-12-28 Univ Columbia TARGETING OF THE MTOR PATH IN NEUROLOGICAL DISEASES
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
BR112015029455A8 (pt) 2013-05-28 2020-03-17 Astrazeneca Ab compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2017031427A1 (en) * 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
SMT202400141T1 (it) * 2015-12-17 2024-05-14 Merck Patent Gmbh 8-ciano-5-piperidino-chinoline come antagonisti di tlr7/8 e loro usi per trattamento di disturbi immunitari
WO2017182495A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
SG11201909924VA (en) 2017-05-02 2019-11-28 Revolution Medicines Inc Rapamycin analogs as mtor inhibitors
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN111315750B (zh) 2017-11-06 2022-12-23 南京明德新药研发有限公司 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
WO2019185117A1 (en) * 2018-03-26 2019-10-03 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) New compounds with enhanced anti-tumor effects
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
BR112020022201A2 (pt) 2018-05-01 2021-02-02 Revolution Medicines, Inc. análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
CA3111980A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
WO2020147842A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
JP7307817B2 (ja) * 2019-05-06 2023-07-12 メッドシャイン ディスカバリー インコーポレイテッド ｍＴＯＲＣ１／２デュアルキナーゼ活性阻害剤の塩形、結晶形及びその製造方法
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
CU20220065A7 (es) 2020-05-04 2023-06-13 Amgen Inc Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
US20240208964A1 (en) * 2020-06-03 2024-06-27 Pyridopyrimidines And Methods Of Their Use Pyridopyrimidines and methods of their use
EP4294431A4 (en) 2021-02-16 2025-05-07 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles based on amphiphilic peptides
IL308167A (en) * 2021-05-04 2023-12-01 Vigil Neuroscience Inc Heterocyclic compounds as agonists for an excitatory receptor expressed on myeloid cells 2 and methods of use
EP4444289A4 (en) * 2021-12-08 2025-12-17 Kineta Inc PYRIDOPYRIMIDINS AND METHODS FOR THEIR USE
CN119604293A (zh) 2022-05-25 2025-03-11 锐新医药公司 用mTOR抑制剂治疗癌症的方法
US20240269269A1 (en) 2022-10-25 2024-08-15 Vaccitech North America, Inc. Self-Assembling Nanoparticles
WO2024233848A1 (en) * 2023-05-10 2024-11-14 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
GB202319857D0 (en) * 2023-12-21 2024-02-07 Tay Therapeutics Ltd Compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4832899A (pl) 1971-08-28 1973-05-02
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
TW313648B (pl) 1995-05-10 1997-08-21 Nintendo Co Ltd
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) * 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE69837529T2 (de) * 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
GB9900334D0 (en) * 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
CA2382435C (en) * 1999-09-07 2009-02-03 Syngenta Participations Ag Novel herbicidally active phenyl-substituted heterocycles
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
JP4186355B2 (ja) * 1999-11-24 2008-11-26 株式会社デンソー Ｃｓｍａ方式対応無線ｌａｎ用アンテナ装置及び端末局
ATE369359T1 (de) * 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
CN1431999A (zh) * 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP4859460B2 (ja) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
JP2008531537A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
KR20070113252A (ko) * 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
EP1899332A1 (en) 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva
EA200801045A1 (ru) * 2005-10-12 2008-10-30 Кэнсер Рисерч Текнолоджи Лтд. Способы и композиции для лечения иммунных нарушений
HRP20120963T1 (hr) 2005-11-22 2012-12-31 Kudos Pharmaceuticals Ltd PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
BRPI0715888B1 (pt) * 2006-08-23 2021-11-03 Kudos Pharmaceuticals Limited Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
CY1119381T1 (el) 2018-02-14
IL196775A0 (en) 2009-11-18
BRPI0715888A2 (pt) 2013-09-17
SA07280461B1 (ar) 2012-04-07
TW200817395A (en) 2008-04-16
KR20090042855A (ko) 2009-04-30
RS55881B1 (sr) 2017-08-31
BRPI0715888A8 (pt) 2018-04-17
CA2659851C (en) 2014-02-25
ES2648388T3 (es) 2018-01-02
KR101438245B1 (ko) 2014-09-04
AU2007287430A1 (en) 2008-02-28
JP5227321B2 (ja) 2013-07-03
JP5629343B2 (ja) 2014-11-19
US8101602B2 (en) 2012-01-24
AR062503A1 (es) 2008-11-12
US8435985B2 (en) 2013-05-07
CO6150164A2 (es) 2010-04-20
LT2057156T (lt) 2017-05-25
US9717736B2 (en) 2017-08-01
CA2659851A1 (en) 2008-02-28
US20160067258A1 (en) 2016-03-10
US20170281637A1 (en) 2017-10-05
BRPI0715888B1 (pt) 2021-11-03
US20080081809A1 (en) 2008-04-03
US9102670B2 (en) 2015-08-11
NO342383B1 (no) 2018-05-14
US10034884B2 (en) 2018-07-31
EP2057156A1 (en) 2009-05-13
CL2007002448A1 (es) 2008-05-16
IL196775A (en) 2017-05-29
JP2010501535A (ja) 2010-01-21
HUE033894T2 (en) 2018-01-29
NZ575672A (en) 2011-10-28
US20110124638A1 (en) 2011-05-26
MX2009001946A (es) 2009-03-05
US7902189B2 (en) 2011-03-08
JP2013107915A (ja) 2013-06-06
US20120142673A1 (en) 2012-06-07
NO20090443L (no) 2009-03-27
AU2007287430B2 (en) 2011-07-21
SI2057156T1 (sl) 2017-06-30
RU2445312C2 (ru) 2012-03-20
TWI406863B (zh) 2013-09-01
DK2057156T3 (en) 2017-05-08
HRP20170627T1 (hr) 2017-06-30
WO2008023161A1 (en) 2008-02-28
RU2009110261A (ru) 2010-09-27
EP2057156B1 (en) 2017-02-01
PT2057156T (pt) 2017-05-04
US20140135315A1 (en) 2014-05-15
MY148688A (en) 2013-05-31

Similar Documents

Publication Publication Date Title
PL2057156T3 (pl) Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR
PL1954699T3 (pl) Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
IL193413A0 (en) Pyrrolidine derivatives as erk inhibitors
ZA200900992B (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
EP2078001B8 (en) Diazepane-acetamide derivatives as selective 11 -hsd1 inhibitors
PL2094263T3 (pl) Pochodne 2-adamantylo-butyroamidowe jako selektywne inhibitory 11beta-HSD1
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
IL199019A0 (en) Acylaminopyrazoles as fgfr inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200808966B (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
PL2069310T3 (pl) Pochodne sulfonylopirazolino-1-karboksyamidyny jako antagoniści 5-HT6
EP1993535A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
EP1993536A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
ZA200804104B (en) Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
IL196807A0 (en) Inhibitors for glyt-1
ZA200809113B (en) Pyrimidine derivatives as p13k inhibitors
SI1954699T1 (sl) Derivati pirido-, pirazo in pirimidopirimidina kot inhibitorji mTOR
HK1120508A (en) Kinase inhibitors